Bergmark BA, O’Donoghue ML, Murphy SA, et al. - This study was undertaken to determine if evolocumab reduces the risk of aortic valve stenosis events in patients with atherosclerotic cardiovascular disease. Participants in the study were randomized 1:1 to evolocumab or placebo. Findings suggested an association of elevated lipoprotein(a) concentrations with higher rates of aortic stenosis events, including aortic valve replacement, in this secondary analysis of 63 patients in a randomized clinical trial. Findings revealed that the overall hazard ratio for aortic stenosis events with evolocumab was 0.66, with no clear correlation in the first year but a hazard ratio of 0.48 after the first year of treatment. Long-term evolocumab therapy can reduce the risk of events of aortic stenosis although these results require confirmation in a dedicated randomized clinical trial.